Bioretec Ltd Announces Registration of 60,000 New Shares Under 2018-1A Option Program

Bioretec Ltd's New Share Registration Bolsters Market Position

On May 20, 2025, Bioretec Ltd, a Finnish medical device company, officially registered 60,000 new shares subscribed under its option rights program known as 2018-1A. This significant move aligns with the company's ongoing strategy to enhance its market presence and equity position in the medical technology sector.

The total subscription price for these new shares was recorded at EUR 90,000, which will contribute to Bioretec's reserve of invested unrestricted equity. Notably, this registration does not alter the company's overall share capital, maintaining it at a stable rate. The recent changes lead to a new total of 24,626,474 shares currently outstanding at Bioretec.

Implications of New Share Registration

The registered shares are set to be issued in the book-entry system by May 21, 2025. This step is crucial in conferring shareholder rights to the investors as immediately recognized on their accounts. Moreover, trading of the new shares is anticipated to commence on the Nasdaq First North Growth Market Finland by May 22, providing further liquidity and accessibility for investors and stakeholders alike.

Bioretec has earned a reputable standing in the medical device field, particularly in the development of biodegradable orthopedic implants. Their innovative RemeOs™ product line, which utilizes a unique magnesium alloy and hybrid composite material, aims to enhance surgical outcomes significantly. Such technology is designed to be absorbed by the body over time, thereby obviating the need for removal surgeries after the healing process, a common challenge in traditional orthopedic care.

The Path Ahead for Bioretec

The functionality of Bioretec's biodegradable implants positions the company well within the global orthopedic market, which is anticipated to exceed USD 9 billion. With regulatory clearances already achieved, such as the first RemeOs™ product market authorization obtained in the United States in March 2023, and a corresponding CE mark approval in Europe secured in January 2025, Bioretec is strategically poised for growth and innovation.

As the industry progresses towards value-based healthcare, Bioretec's solutions promise not only to advance patient outcomes but also to support healthcare providers in their efforts to deliver cost-effective care. The company's commitment to improving healing processes and enhancing life quality reflects its core philosophy, encapsulated in their motto: “Better healing - Better life.”

For further inquiries, interested parties may contact Sarah van Hellenberg Hubar-Fisher, interim CEO at +31 6 1544 8736, or Johanna Salko, CFO at +358 40 754 8172. For investors seeking additional insights, Nordic Certified Adviser AB can also be approached at +46 70 551 67 29.

Bioretec's commitment to reshaping the landscape of surgical treatment for bone fractures showcases its potential as a game changer in the orthopedic sector. As the company advances into new territories and continues its innovation trajectory, stakeholders are optimistic about its forthcoming milestones and market influence.